Vancomycin-resistant Staphylococcus aureus: no apocalypse now.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Microbiology and Infection

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1469-0691.2003.00734.XPMID 14616695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emergence of Methicillin-Resistant Staphylococcus aureus with Intermediate Glycopeptide Resistance

  2012cited by this paper
• Treatment failure due to methicillin‐resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin

  2002cited by this paper
• In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus.

  2001cited by this paper
• Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.

  2001cited by this paper
• Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

  2001cited by this paper
• Treatment failure due to methicillin‐resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin

  2001cited by this paper
• First Report of Methicillin-ResistantStaphylococcus aureus with Reduced Susceptibility to Vancomycin in Thailand

  2001cited by this paper
• Clinicopathological Study of Early Adenocarcinoma of the Gastric Cardia: Comparison with Early Adenocarcinoma of the Distal Stomach and Esophagus

  2001cited by this paper
• Glycopeptide-intermediate Staphylococcus aureus: rediscovery of an old problem?

  2000cited by this paper
• Outbreak of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Glycopeptides in a Parisian Hospital

  2000cited by this paper
• Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals.

  2000cited by this paper
• Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50

  2000cited by this paper
• In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus.

  2000cited by this paper
• Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

  1999cited by this paper
• Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.

  1999cited by this paper
• Bacteremia caused by staphylococci with inducible vancomycin heteroresistance.

  1999cited by this paper
• Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin

  1999cited by this paper
• Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

  1999cited by this paper
• Interactions between Methicillin and Vancomycin in Methicillin-Resistant Staphylococcus aureus Strains Displaying Different Phenotypes of Vancomycin Susceptibility

  1999cited by this paper
• Vancomycin-resistant Staphylococcus aureus.

  1998cited by this paper
• Intermediate vancomycin resistance in Staphylococcus aureus: a major threat or a minor inconvenience?

  1998cited by this paper
• First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

  1998cited by this paper
• Vancomycin-resistant Staphylococcus aureus: apocalypse now?

  1997cited by this paper
• Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

  1997cited by this paper
• Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

  1995cited by this paper
• Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex

  1993cited by this paper
• Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility.

  1992cited by this paper
• Failure of teicolpanin treatment associated with an increase in MIC during therapy of Staphylococus aureus septicaemia

  1992cited by this paper
• Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia.

  1992cited by this paper
• Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.

  1991cited by this paper
• Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin

  1990cited by this paper
• Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.

  1990cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vancomycin-resistant Staphylococcus Aureus: a New Model of Antibiotic Resistance

  year unknowncited by this paper

• Immunitary Life

  2019cites this paper
• Biotic Politics: Immunitary Imaginaries in Antimicrobial Resistance (AMR)

  2018cites this paper
• ‘There is worse to come’: The biopolitics of traumatism in antimicrobial resistance (AMR)

  2017cites this paper
• LibGuides: Art: Open Access Introduction

  2017cites this paper
• Emergence of Vancomycin Intermediate Staphylococcus aureus ( VISA ) in a Tertiary Care Hospital in Lahore : An Alarming Situation

  2015cites this paper
• Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia

  2013cites this paper
• DRUG RESISTANCE OF OPPORTUNISTIC BACTERIA, ISOLATED FROM THE PATIENТS WITH HIV-INFECTION

  2013cites this paper
• Synergistic Activity of Ceftobiprole and Vancomycin in a Rat Model of Infective Endocarditis Caused by Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus

  2012cites this paper
• [Dosage adjustment of vancomycin in continuous infusion in critically ill-patients].

  2010cites this paper
• Ajustement de la posologie de la vancomycine administrée en perfusion continue chez des patients de réanimation

  2010cites this paper
• Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

  2009cites this paper
• “The post-antibiotic apocalypse” and the “war on superbugs”: catastrophe discourse in microbiology, its rhetorical form and political function

  2009cites this paper
• Emergence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Asia

  2008cites this paper
• [Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children].

  2008cites this paper
• The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

  2007cites this paper
• Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia.

  2007cites this paper
• Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist.

  2007cites this paper
• Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate

  2007cites this paper
• Treatment options for multidrug-resistant bacteria

  2006cites this paper
• Hip arthroplasty infection with heterogeneous vancomycin-resistant Staphylococcus aureus

  2006cites this paper
• The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus.

  2006cites this paper
• July 2006;21(10)-PharmaNote.pub

  2006cites this paper
• Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.

  2006cites this paper
• Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.

  2005cites this paper
• Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus

  2005cites this paper
• Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA).

  2005cites this paper
• The real vancomycin-resistant Staphylococcus aureus has arrived

  2005cites this paper
• Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.

  2005cites this paper
• Aureus Staphylococcus Methicillin-resistant Teicoplanin-resistant Derivative of Other Virulence Factors in a Modulation of Fibronectin Adhesins And

  2004cites this paper
• False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods.

  2004cites this paper
• tcaA Inactivation Increases Glycopeptide Resistance in Staphylococcus aureus

  2004cites this paper
• Modulation of Fibronectin Adhesins and Other Virulence Factors in a Teicoplanin-Resistant Derivative of Methicillin-Resistant Staphylococcus aureus

  2004cites this paper
• Linezolid in VAP by MRSA: a better choice?

  2004cites this paper
• Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.

  2004cites this paper
• Quality Control Guidelines for BAL9141 (Ro 63-9141), an Investigational Cephalosporin, When Reference MIC and Standardized Disk Diffusion Susceptibility Test Methods Are Used

  2004cites this paper
• Annals of Clinical Microbiology and Antimicrobials Open Access a Multi-center Blinded Study on the Efficiency of Phenotypic Screening Methods to Detect Glycopeptide Intermediately Susceptible Staphylococcus Aureus (gisa) and Heterogeneous Gisa (h-gisa)

  year unknowncites this paper